Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics

Gondhowiardjo, 2021, Five-year cancer epidemiology at the national referral hospital: hospital-based cancer registry data in Indonesia, JCO Glob. Oncol., 7, 190, 10.1200/GO.20.00155 Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 Hu, 2020, Roles of estrogen receptor α and β in the regulation of proliferation in endometrial carcinoma, Pathol. Res. Pract., 216, 10.1016/j.prp.2020.153149 Gülseren, 2020, Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?, Curr. Probl. Cancer, 44, 10.1016/j.currproblcancer.2019.07.003 Salem, 2004, Estrogen, a double-edged sword: modulation of TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production, Curr. Drug Targets Inflamm. Allergy, 3, 97, 10.2174/1568010043483944 Sobral-Leite, 2018, Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival, Oncoimmunology, 7, 10.1080/2162402X.2018.1509820 Romero, 2020, Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells, Cancer Immunol. Immunother., 69, 43, 10.1007/s00262-019-02437-2 Liu, 2018, ERα is a negative regulator of PD-L1 gene transcription in breast cancer, Biochem. Biophys. Res. Commun., 505, 157, 10.1016/j.bbrc.2018.09.005 Kosvyra, 2019, Developing an integrated genomic profile for cancer patients with the use of NGS data, Emerg. Sci. J., 3, 157, 10.28991/esj-2019-01178 Engerud, 2020, High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer, Gynecol. Oncol., 157, 260, 10.1016/j.ygyno.2020.01.020 Yamashita, 2017, Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer, Oncotarget, 9, 5652, 10.18632/oncotarget.23790 Zong, 2021, PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer, Gynecol. Oncol., 162, 631, 10.1016/j.ygyno.2021.07.009 Salama, 2022, Immunohistochemical expression of programmed death ligand 1(PDL1) in endometrial carcinoma and its relation to CD4 and CD8 positive immune cells, Asian Pac. J. Cancer Prev., 23, 2491, 10.31557/APJCP.2022.23.7.2491 Chen, 2022, Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma, Mod. Pathol., 35, 1955, 10.1038/s41379-022-01131-6 Disis, 2023, Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer, J. Immunother. Cancer, 11, 10.1136/jitc-2022-006624 Musacchio, 2020, Immune checkpoint inhibitors: a promising choice for endometrial cancer patients?, J. Clin. Med., 9, 1, 10.3390/jcm9061721 Rizzo, 2022, Immune checkpoint inhibitors and mismatch repair status in advanced endometrial cancer: elective affinities, J. Clin. Med., 11, 3912, 10.3390/jcm11133912 Tinker, 2023, A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer, Ther. Adv. Med. Oncol., 15, 10.1177/17588359231157633 Wang, 2020, Estrogen receptor, progesterone receptor, and HER2 receptor markers in endometrial cancer, J. Cancer, 11, 1693, 10.7150/jca.41943 Zhang, 2020, PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas, BMC Cancer, 20, 1 Chew, 2022, PD-L1 expression in endometrial cancer and its association with clinicopathological features: a systematic review and meta-analysis, Cancers, 14 Pasanen, 2020, PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups, Am. J. Surg. Pathol., 44, 174, 10.1097/PAS.0000000000001395 Shah, 2022, Correlation between age and hormone receptor status in women with breast cancer, Cureus, 14 Chauhan, 2020, A comparative analysis of body mass index with estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in pre- and postmenopausal breast cancer patients, J. Midlife Health, 11, 210 Moreira, 2022, Body mass index and immune checkpoint inhibitor efficacy in metastatic cancer patients: a Brazilian retrospective study, Front. Urol., 2, 10.3389/fruro.2022.1069045 Milkov, 2018, Expression of progesterone and estrogen receptors in endometrial carcinoma and myoma in postmenopausal women assessment of PR and ER in the uterus, Biomed. J. Sci. Tech. Res., 11, 8257 Kim, 2018, Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer, Gynecol. Oncol., 149, 381, 10.1016/j.ygyno.2018.02.013 Manan, 2021, Prognostic significance of hormone receptor (ER/PR) status inendometrial carcinoma in black women: implications with lymph node metastasis, Int. J. Cancer Clin. Res., 8, 150 Li, 2018, Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer, BMC Cancer, 18 Vahrenkamp, 2018, Clinical and genomic crosstalk between glucocorticoid receptor and estrogen receptor α in endometrial cancer, Cell Rep., 22, 2995, 10.1016/j.celrep.2018.02.076